{"pmid":32370558,"title":"Atrial Arrhythmias in a Patient Presenting With Coronavirus Disease-2019 (COVID-19) Infection.","text":["Atrial Arrhythmias in a Patient Presenting With Coronavirus Disease-2019 (COVID-19) Infection.","The coronavirus disease-2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) that has significant potential cardiovascular implications for patients. These include myocarditis, acute coronary syndromes, cardiac arrhythmias, cardiomyopathies with heart failure and cardiogenic shock, and venous thromboembolic events. We describe a Caribbean-Black gentleman with COVID-19 infection presenting with atrial arrhythmias, namely, atrial flutter and atrial fibrillation, which resolved with rate and rhythm control strategies, and supportive care.","J Investig Med High Impact Case Rep","Seecheran, Rajeev","Narayansingh, Roshni","Giddings, Stanley","Rampaul, Marlon","Furlonge, Kurt","Abdool, Kamille","Bhagwandass, Neal","Seecheran, Naveen Anand","32370558"],"abstract":["The coronavirus disease-2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) that has significant potential cardiovascular implications for patients. These include myocarditis, acute coronary syndromes, cardiac arrhythmias, cardiomyopathies with heart failure and cardiogenic shock, and venous thromboembolic events. We describe a Caribbean-Black gentleman with COVID-19 infection presenting with atrial arrhythmias, namely, atrial flutter and atrial fibrillation, which resolved with rate and rhythm control strategies, and supportive care."],"journal":"J Investig Med High Impact Case Rep","authors":["Seecheran, Rajeev","Narayansingh, Roshni","Giddings, Stanley","Rampaul, Marlon","Furlonge, Kurt","Abdool, Kamille","Bhagwandass, Neal","Seecheran, Naveen Anand"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32370558","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1177/2324709620925571","keywords":["covid-19","sars-cov-2","atrial arrhythmias","atrial fibrillation","atrial flutter","coronavirus disease 2019","severe acute respiratory syndrome coronavirus 2"],"topics":["Case Report"],"weight":1,"_version_":1666138496317784064,"score":9.490897,"similar":[{"pmid":32453074,"title":"Atrial Fibrillation in COVID-19: From epidemiological association to pharmacological implications.","text":["Atrial Fibrillation in COVID-19: From epidemiological association to pharmacological implications.","Coronavirus disease 2019 (COVID-19) outbreak is a public health emergency of international concern due to a highly pathogenic human coronavirus (HCoV), actually named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite much emerging data about the epidemiological association between cardiovascular diseases and COVID-19, little is still known atrial fibrillation (AF) and its optimal management in this clinical contest. The aim of our review is to describe the pharmacological interactions between cardiovascular drugs more commonly used in AF management and experimental COVID-19 therapies, based on European (EU) and Unites States (US) summaries of product characteristics.","J Cardiovasc Pharmacol","Russo, Vincenzo","Rago, Anna","Carbone, Andreina","Bottino, Roberta","Ammendola, Ernesto","Della Cioppa, Nadia","Galante, Dario","Golino, Paolo","Nigro, Gerardo","32453074"],"abstract":["Coronavirus disease 2019 (COVID-19) outbreak is a public health emergency of international concern due to a highly pathogenic human coronavirus (HCoV), actually named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite much emerging data about the epidemiological association between cardiovascular diseases and COVID-19, little is still known atrial fibrillation (AF) and its optimal management in this clinical contest. The aim of our review is to describe the pharmacological interactions between cardiovascular drugs more commonly used in AF management and experimental COVID-19 therapies, based on European (EU) and Unites States (US) summaries of product characteristics."],"journal":"J Cardiovasc Pharmacol","authors":["Russo, Vincenzo","Rago, Anna","Carbone, Andreina","Bottino, Roberta","Ammendola, Ernesto","Della Cioppa, Nadia","Galante, Dario","Golino, Paolo","Nigro, Gerardo"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32453074","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1097/FJC.0000000000000854","locations":["optimal","Unites States","US"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Treatment"],"weight":1,"_version_":1667983494569000961,"score":209.71338},{"pmid":32453685,"title":"Acute Cerebral Stroke with Multiple Infarctions and COVID-19, France, 2020.","text":["Acute Cerebral Stroke with Multiple Infarctions and COVID-19, France, 2020.","We describe 2 cases in coronavirus disease patients in France involving presumed thrombotic stroke that occurred during ongoing anticoagulation treatment for atrial fibrillation stroke prophylaxis; 1 patient had positive antiphospholipid antibodies. These cases highlight the severe and unique consequences of coronavirus disease-associated stroke.","Emerg Infect Dis","Zayet, Souheil","Klopfenstein, Timothee","Kovacs, Robert","Stancescu, Silviu","Hagenkotter, Beate","32453685"],"abstract":["We describe 2 cases in coronavirus disease patients in France involving presumed thrombotic stroke that occurred during ongoing anticoagulation treatment for atrial fibrillation stroke prophylaxis; 1 patient had positive antiphospholipid antibodies. These cases highlight the severe and unique consequences of coronavirus disease-associated stroke."],"journal":"Emerg Infect Dis","authors":["Zayet, Souheil","Klopfenstein, Timothee","Kovacs, Robert","Stancescu, Silviu","Hagenkotter, Beate"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32453685","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.3201/eid2609.201791","keywords":["2019 novel coronavirus disease","covid-19","coronavirus diseases","france","sars-cov-2","central nervous system","infarction","pneumonia","respiratory diseases","severe acute respiratory syndrome coronavirus 2","stroke","viruses","zoonoses"],"locations":["France","France"],"countries":["France"],"countries_codes":["FRA|France"],"topics":["Case Report"],"weight":1,"_version_":1667983494557466626,"score":200.5858},{"pmid":32354800,"title":"Cardiovascular manifestations and treatment considerations in covid-19.","text":["Cardiovascular manifestations and treatment considerations in covid-19.","Since its recognition in December 2019, covid-19 has rapidly spread globally causing a pandemic. Pre-existing comorbidities such as hypertension, diabetes, and cardiovascular disease are associated with a greater severity and higher fatality rate of covid-19. Furthermore, covid-19 contributes to cardiovascular complications, including acute myocardial injury as a result of acute coronary syndrome, myocarditis, stress-cardiomyopathy, arrhythmias, cardiogenic shock, and cardiac arrest. The cardiovascular interactions of covid-19 have similarities to that of severe acute respiratory syndrome, Middle East respiratory syndrome and influenza. Specific cardiovascular considerations are also necessary in supportive treatment with anticoagulation, the continued use of renin-angiotensin-aldosterone system inhibitors, arrhythmia monitoring, immunosuppression or modulation, and mechanical circulatory support.","Heart","Kang, Yu","Chen, Tiffany","Mui, David","Ferrari, Victor","Jagasia, Dinesh","Scherrer-Crosbie, Marielle","Chen, Yucheng","Han, Yuchi","32354800"],"abstract":["Since its recognition in December 2019, covid-19 has rapidly spread globally causing a pandemic. Pre-existing comorbidities such as hypertension, diabetes, and cardiovascular disease are associated with a greater severity and higher fatality rate of covid-19. Furthermore, covid-19 contributes to cardiovascular complications, including acute myocardial injury as a result of acute coronary syndrome, myocarditis, stress-cardiomyopathy, arrhythmias, cardiogenic shock, and cardiac arrest. The cardiovascular interactions of covid-19 have similarities to that of severe acute respiratory syndrome, Middle East respiratory syndrome and influenza. Specific cardiovascular considerations are also necessary in supportive treatment with anticoagulation, the continued use of renin-angiotensin-aldosterone system inhibitors, arrhythmia monitoring, immunosuppression or modulation, and mechanical circulatory support."],"journal":"Heart","authors":["Kang, Yu","Chen, Tiffany","Mui, David","Ferrari, Victor","Jagasia, Dinesh","Scherrer-Crosbie, Marielle","Chen, Yucheng","Han, Yuchi"],"date":"2020-05-02T11:00:00Z","year":2020,"_id":"32354800","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1136/heartjnl-2020-317056","keywords":["cardiac risk factors and prevention","myocarditis","systemic inflammatory diseases"],"e_drugs":["Aldosterone"],"topics":["Treatment"],"weight":1,"_version_":1666138495230410753,"score":197.50986},{"pmid":32383763,"title":"Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy.","text":["Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy.","AIMS: To compare demographic characteristics, clinical presentation, and outcomes of patients with and without concomitant cardiac disease, hospitalized for COVID-19 in Brescia, Lombardy, Italy. METHODS AND RESULTS: The study population includes 99 consecutive patients with COVID-19 pneumonia admitted to our hospital between 4 March and 25 March 2020. Fifty-three patients with a history of cardiac disease were compared with 46 without cardiac disease. Among cardiac patients, 40% had a history of heart failure, 36% had atrial fibrillation, and 30% had coronary artery disease. Mean age was 67 +/- 12 years, and 80 (81%) patients were males. No differences were found between cardiac and non-cardiac patients except for higher values of serum creatinine, N-terminal probrain natriuretic peptide, and high sensitivity troponin T in cardiac patients. During hospitalization, 26% patients died, 15% developed thrombo-embolic events, 19% had acute respiratory distress syndrome, and 6% had septic shock. Mortality was higher in patients with cardiac disease compared with the others (36% vs. 15%, log-rank P = 0.019; relative risk 2.35; 95% confidence interval 1.08-5.09). The rate of thrombo-embolic events and septic shock during the hospitalization was also higher in cardiac patients (23% vs. 6% and 11% vs. 0%, respectively). CONCLUSIONS: Hospitalized patients with concomitant cardiac disease and COVID-19 have an extremely poor prognosis compared with subjects without a history of cardiac disease, with higher mortality, thrombo-embolic events, and septic shock rates.","Eur Heart J","Inciardi, Riccardo M","Adamo, Marianna","Lupi, Laura","Cani, Dario S","Di Pasquale, Mattia","Tomasoni, Daniela","Italia, Leonardo","Zaccone, Gregorio","Tedino, Chiara","Fabbricatore, Davide","Curnis, Antonio","Faggiano, Pompilio","Gorga, Elio","Lombardi, Carlo M","Milesi, Giuseppe","Vizzardi, Enrico","Volpini, Marco","Nodari, Savina","Specchia, Claudia","Maroldi, Roberto","Bezzi, Michela","Metra, Marco","32383763"],"abstract":["AIMS: To compare demographic characteristics, clinical presentation, and outcomes of patients with and without concomitant cardiac disease, hospitalized for COVID-19 in Brescia, Lombardy, Italy. METHODS AND RESULTS: The study population includes 99 consecutive patients with COVID-19 pneumonia admitted to our hospital between 4 March and 25 March 2020. Fifty-three patients with a history of cardiac disease were compared with 46 without cardiac disease. Among cardiac patients, 40% had a history of heart failure, 36% had atrial fibrillation, and 30% had coronary artery disease. Mean age was 67 +/- 12 years, and 80 (81%) patients were males. No differences were found between cardiac and non-cardiac patients except for higher values of serum creatinine, N-terminal probrain natriuretic peptide, and high sensitivity troponin T in cardiac patients. During hospitalization, 26% patients died, 15% developed thrombo-embolic events, 19% had acute respiratory distress syndrome, and 6% had septic shock. Mortality was higher in patients with cardiac disease compared with the others (36% vs. 15%, log-rank P = 0.019; relative risk 2.35; 95% confidence interval 1.08-5.09). The rate of thrombo-embolic events and septic shock during the hospitalization was also higher in cardiac patients (23% vs. 6% and 11% vs. 0%, respectively). CONCLUSIONS: Hospitalized patients with concomitant cardiac disease and COVID-19 have an extremely poor prognosis compared with subjects without a history of cardiac disease, with higher mortality, thrombo-embolic events, and septic shock rates."],"journal":"Eur Heart J","authors":["Inciardi, Riccardo M","Adamo, Marianna","Lupi, Laura","Cani, Dario S","Di Pasquale, Mattia","Tomasoni, Daniela","Italia, Leonardo","Zaccone, Gregorio","Tedino, Chiara","Fabbricatore, Davide","Curnis, Antonio","Faggiano, Pompilio","Gorga, Elio","Lombardi, Carlo M","Milesi, Giuseppe","Vizzardi, Enrico","Volpini, Marco","Nodari, Savina","Specchia, Claudia","Maroldi, Roberto","Bezzi, Michela","Metra, Marco"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32383763","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1093/eurheartj/ehaa388","keywords":["covid-19","cardiovascular disease","mortality","pneumonia"],"locations":["Brescia","Lombardy","Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"e_drugs":["Creatinine"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666419683368108032,"score":183.76038},{"pmid":32441876,"title":"Cutaneous small vessel vasculitis secondary to COVID-19 infection: A case report.","text":["Cutaneous small vessel vasculitis secondary to COVID-19 infection: A case report.","We present a case of an 83-year-old woman with a history of hypertension, transient ischemic attack (TIA), atrial fibrillation, chronic renal impairment presented to our dermatology emergency room on April 9, 2020, for evaluation of purple palpable papules and serohaematic blisters on both her lower legs, feet and toes that had appeared 5 days earlier (Figure 1).","J Eur Acad Dermatol Venereol","Mayor-Ibarguren, A","Feito-Rodriguez, M","Quintana Castanedo, L","Ruiz-Bravo, E","Montero Vega, D","Herranz-Pinto, P","32441876"],"abstract":["We present a case of an 83-year-old woman with a history of hypertension, transient ischemic attack (TIA), atrial fibrillation, chronic renal impairment presented to our dermatology emergency room on April 9, 2020, for evaluation of purple palpable papules and serohaematic blisters on both her lower legs, feet and toes that had appeared 5 days earlier (Figure 1)."],"journal":"J Eur Acad Dermatol Venereol","authors":["Mayor-Ibarguren, A","Feito-Rodriguez, M","Quintana Castanedo, L","Ruiz-Bravo, E","Montero Vega, D","Herranz-Pinto, P"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32441876","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/jdv.16670","keywords":["covid-19","cutaneous small vessel vasculitis","leukocytoclastic vasculitis","sars-cov-2"],"topics":["Case Report"],"weight":1,"_version_":1667523504878125057,"score":178.87656}]}